SEMAX, SELANK, ADAMAX, PE-22-28, Cerebrolysin, VIP, DSIP, and Dermorphin are often placed together in discussions of neuropeptide research, but they are not interchangeable compounds and they do not share one uniform evidence base. Some are defined synthetic peptides, some are derived from naturally occurring peptide systems, one is a complex peptide mixture, and several have very different levels of published independent research behind them.
For researchers and procurement readers, that distinction matters before a catalog listing, purity percentage, or Certificate of Analysis is even considered.
Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.
Research-use notice: CertaPeptides products discussed here are intended for controlled laboratory and in-vitro research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, cosmetics, supplements, or personal experimentation.
Qualified research buyers exploring the relevant CertaPeptides catalog can use CertaPeptides LOOT30 for up to 30% off. The code is LOOT30. The useful part of this article, however, is understanding what these names actually identify, how their research contexts differ, and what documentation should be checked before two products are treated as scientifically comparable.
Why these eight names should not be treated as one peptide category
The label "neuropeptide" is convenient, but it can hide major differences.
SEMAX is a synthetic heptapeptide based on the ACTH(4-7) fragment with a Pro-Gly-Pro extension. SELANK is a synthetic heptapeptide related to the endogenous immunomodulatory peptide tuftsin. PE-22-28 is a seven-amino-acid fragment developed from work on spadin and the TREK-1 potassium channel. VIP, or vasoactive intestinal peptide, is an endogenous signaling peptide with broad neuroendocrine and peripheral biological roles.
Dermorphin is a naturally occurring opioid peptide originally characterized from amphibian skin and is structurally notable for containing a D-amino acid. DSIP, or delta sleep-inducing peptide, belongs to a very different historical research program and has an unusually uncertain biological interpretation despite decades of study.
Cerebrolysin requires an additional distinction: it is not simply another short synthetic peptide with one sequence. Published literature describes it as a preparation containing low-molecular-weight peptides and amino acids derived from porcine brain. Therefore, a researcher reading documentation for Cerebrolysin should not apply the same expectations used for a sequence-defined compound such as SEMAX or PE-22-28.
ADAMAX is also a useful cautionary example. Commercial descriptions place it in neuropeptide or bioregulator research contexts, but its independent literature footprint is substantially thinner than the literature surrounding better-characterized entities such as VIP, Semax, Selank, or the spadin-derived PE-22-28. A catalog description should therefore not be mistaken for equivalent evidence.
That is the first documentation lesson: a similar commercial category does not imply a similar molecular identity, mechanism, analytical method, or evidence level.
Readers wanting a narrower comparison of the first four names can also consult the previously published CertaPeptides SEMAX vs SELANK vs ADAMAX vs PE-22-28 research distinctions.
SEMAX: read the sequence before reading the claims
SEMAX is commonly described as an ACTH-fragment-derived synthetic peptide. The sequence usually associated with Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The ACTH(4-7)-derived portion and the Pro-Gly-Pro extension are important because "Semax" should identify a defined molecular entity rather than a broad family name.
Published experimental work has examined Semax in neurotrophin-expression and cerebral-ischemia models. One PubMed-indexed study reported that Semax and the Pro-Gly-Pro fragment altered transcription of neurotrophins and their receptors after cerebral ischemia in rats. Another body of research has examined changes involving BDNF, NGF, and related signaling.
This evidence needs careful wording. Findings in a rat cerebral-ischemia model are evidence about an experimental model. They do not automatically establish a therapeutic outcome in humans, and they certainly do not turn a commercial research product into an approved medicine.
A later functional-connectivity study also evaluated Semax and Selank using resting-state fMRI in human participants. The existence of human research is relevant when mapping the literature, but again it should not be converted into a recommendation to use a research product clinically.
CertaPeptides currently describes its Semax product as a synthetic heptapeptide derived from ACTH(4-7), provides a supplier batch specification, and says selected lots have independent Janoshik testing. Its product information also explicitly frames the compound for laboratory research rather than human or veterinary use.
For documentation review, the practical questions are therefore straightforward:
Does the product name correspond to the expected Semax sequence?
Does the lot identifier on the vial correspond to the documentation being shown?
Does the document report identity, purity, content, or some combination of these?
Does an independent report apply to the exact shipped lot, or is the page showing a representative or selected-lot result?
Those questions matter more than simply seeing a large percentage next to the word "purity."
SELANK: a tuftsin-derived peptide with its own research lineage
SELANK should not be described merely as "similar to Semax." The two are frequently mentioned together, but their origins are different.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived conceptually from tuftsin, the tetrapeptide Thr-Lys-Pro-Arg, with a Pro-Gly-Pro sequence added.
That relationship connects Selank to a research lineage involving tuftsin biology, immune signaling, peptide stability, neurochemistry, and GABA-related mechanisms.
Peer-reviewed work has investigated Selank's interaction with GABA-related systems and other molecular pathways. A 2018 paper indexed in PubMed examined molecular aspects of Selank activity and reported experimental findings involving GABA binding and allosteric modulation. These are mechanistic findings, not permission to translate a laboratory peptide into a personal anxiolytic product.
This is exactly where disciplined terminology becomes important. It is reasonable to write that "Selank has been studied in relation to GABAergic signaling." It is much less defensible to jump directly from that statement to a guaranteed human outcome.
The same caution applies to immune-related research. Tuftsin itself has a significant biochemical literature, but a Selank product should not inherit every claim ever associated with tuftsin. Structural ancestry and biological equivalence are different propositions.
CertaPeptides currently identifies Selank as a synthetic heptapeptide derived from tuftsin and states a supplier batch specification with independent testing on selected lots. The page also distinguishes specific independently tested material from other sizes that may ship under the supplier batch specification.
That last detail is worth noticing because it illustrates why researchers should read documentation at the lot level, not merely the product-name level.
For a broader overview connecting both compounds with the surrounding neuropeptide category, see the previously published CertaPeptides neuropeptide research explainer covering Semax, Selank, Adamax, and PE-22-28.
SEMAX and SELANK: similar catalog neighborhood, different scientific questions
Researchers sometimes compare SEMAX and SELANK because both are short synthetic peptides associated with neuroscience research and both contain a terminal Pro-Gly-Pro motif.
That similarity is real, but it is not enough to make them interchangeable.
Semax traces back to an ACTH-fragment design. Selank traces back to tuftsin. Their historical research programs, proposed molecular targets, and experimental questions are therefore distinct.
One functional-connectivity study examined both Semax and Selank and reported differences involving functional connectivity of brain regions including the amygdala and temporal cortex. That paper can be useful when reviewing how both compounds have appeared within the same experimental framework, but a single comparative study does not collapse their molecular identities into one class.
A laboratory choosing between them should start with the hypothesis.
If a study is designed around neurotrophin-expression pathways historically studied with Semax, then Selank is not automatically a substitute.
If a project is built around tuftsin-derived structures or GABA-related mechanistic questions associated with Selank, then Semax does not become equivalent merely because both are marketed within neuropeptide categories.
The compound must follow the experimental question, not the other way around.
ADAMAX: the evidence gap itself is useful information
ADAMAX presents a different documentation challenge because information available from commercial sources is easier to find than a strong, clearly defined independent peer-reviewed literature under the exact name "Adamax."
CertaPeptides currently describes Adamax as a synthetic neuropeptide fragment associated with the vasopressin analogue family and places it in cognitive-neuroscience and memory research contexts. The page connects that context to historical research on vasopressin-derived fragments.
That background can help explain the category, but it should not be mistaken for direct evidence about every commercial material labelled Adamax.
This distinction is essential:
Evidence about vasopressin does not automatically become evidence about Adamax.
Evidence about a historical vasopressin fragment does not automatically validate a modified commercial compound.
A supplier description is not equivalent to a peer-reviewed structural characterization.
And a purity number does not establish biological efficacy.
When the direct literature under a product's exact name is limited, researchers should become more specific, not less specific.
The documentation file should make the exact molecular identity clear enough that the material can be distinguished from adjacent vasopressin-family peptides and fragments. A laboratory should be able to determine what chemical entity the name "Adamax" refers to, rather than relying only on a branded or informal label.
This is one reason the research-documentation hierarchy matters. Molecular identity comes before mechanistic storytelling.
PE-22-28: one of the clearest examples of why sequence history matters
PE-22-28 has a more traceable experimental lineage.
The peptide is a shortened fragment developed from research on spadin, a peptide connected with the TREK-1 two-pore-domain potassium channel. A 2017 paper in Frontiers in Pharmacology, indexed in PubMed, reported the development and testing of shortened spadin analogues, including PE-22-28.
The paper identified PE-22-28 as a seven-amino-acid peptide and examined TREK-1 inhibition in cellular assays. The study also evaluated the compound and related analogues in animal behavioral models and reported differences in stability and experimental activity relative to spadin.
This is a good example of how evidence should be separated by level.
The cellular TREK-1 experiments are in-vitro mechanistic evidence.
The mouse experiments are animal evidence.
Neither category should be silently rewritten as established clinical efficacy in people.
The literature is nevertheless valuable because it provides a defined research origin, a named molecular target, a sequence-level context, and reproducible experimental questions.
For documentation review, a PE-22-28 listing should therefore be checked against the expected sequence and identity, rather than treated simply as another "brain peptide."
A researcher comparing PE-22-28 with Semax should notice that the conceptual starting points are completely different. Semax comes from an ACTH-fragment research lineage. PE-22-28 comes from spadin/TREK-1 work.
That is a much more scientifically meaningful distinction than placing both in a generic "neuropeptide" menu.
CEREBROLYSIN: a mixture creates different documentation requirements
Cerebrolysin needs to be handled differently from the short sequence-defined peptides in this article.
Published literature describes Cerebrolysin as a porcine-brain-derived preparation containing low-molecular-weight peptides and amino acids. It has been studied in numerous neurological contexts, including dementia and stroke.
The literature is also a good reminder that the presence of clinical research does not automatically produce a simple conclusion. Reviews of Cerebrolysin have reported both positive findings and important uncertainties, and systematic-review literature has evaluated benefits and harms in settings such as acute ischemic stroke.
For a research reader, the key point here is not to adjudicate clinical treatment. It is to understand why a mixture needs a different documentation mindset.
With a single defined peptide, researchers may ask:
What is the sequence?
What is its molecular mass?
Was the expected molecular species identified?
What is the chromatographic purity?
How much material is present?
For a complex peptide hydrolysate, the question "what percentage pure is it?" may not fully describe the material because the intended sample itself is heterogeneous. Composition, molecular-weight distribution, content specifications, source material, manufacturing consistency, and appropriate analytical methods can become more important.
CertaPeptides currently lists Cerebrolysin 60mg and describes it as a peptide hydrolysate derived from porcine brain extract, with a specification relating to the proportion of peptides below a defined molecular-weight range. Its COA area also lists an independently tested Cerebrolysin entry.
Researchers should read that documentation on its own terms instead of expecting Cerebrolysin to produce the same analytical profile as Semax or Selank.
This is one of the most important lessons in the entire comparison:
Analytical documentation must fit the chemistry of the product being analyzed.
VIP: a broad endogenous signaling peptide, not a narrow "brain-only" molecule
VIP stands for vasoactive intestinal peptide.
Despite its name, VIP participates in much more than gastrointestinal biology. It is an endogenous neuropeptide involved in neuroendocrine, neural, immune, vascular, epithelial, and circadian signaling.
Published review literature describes VIP signaling through receptors including VPAC1 and VPAC2 and discusses its wide physiological distribution and functions.
That breadth makes careless summaries particularly risky.
A short commercial description might tempt a writer to choose one fashionable pathway and describe VIP as if that were its sole identity. In reality, its biology spans multiple tissues and signaling systems.
A well-designed laboratory article should therefore specify which VIP question is being studied.
Is the project about receptor pharmacology?
Neuroendocrine signaling?
Immune-cell signaling?
Gastrointestinal epithelial biology?
Circadian-system experiments?
A receptor-binding assay?
The same peptide can appear in each context, but the experimental design and interpretation are different.
The CertaPeptides catalog currently includes VIP among its research compounds. As with the other products discussed here, inclusion in a catalog does not establish medical suitability. The supplier's research-use framing remains the relevant commercial-use limitation.
DSIP: a classic name with unusually unresolved biology
DSIP means delta sleep-inducing peptide.
The name sounds more definitive than the evidence.
Historical studies reported sleep-related and other physiological effects, and reviews from the 1980s described a nonapeptide investigated in sleep, neuroendocrine, electrophysiological, and behavioral research.
However, later scientific reviews emphasized unresolved questions around DSIP's natural occurrence, physiological role, and even the strength of the original "sleep factor" concept.
One review went so far as to describe DSIP as a "still unresolved riddle" and concluded that the sleep-factor hypothesis was poorly documented.
That history makes DSIP a useful lesson in source literacy.
Researchers should not infer from the compound's name that "delta sleep-inducing peptide" means a settled molecular sleep mechanism. Scientific names often preserve the historical circumstances under which compounds were discovered or proposed; they do not guarantee that every early hypothesis survived subsequent investigation.
A responsible article therefore says that DSIP has been studied in connection with sleep and other physiological processes, while also stating that its endogenous biology and mechanistic interpretation remain uncertain.
That distinction is more scientifically informative than repeating a commercial slogan.
DERMORPHIN: structurally unusual and pharmacologically distinct
Dermorphin is very different from Semax, Selank, PE-22-28, or DSIP.
It is a naturally occurring opioid peptide first identified in secretions from Phyllomedusa frogs. A particularly unusual structural feature is the D-alanine residue in its sequence. Naturally occurring D-amino acids in bioactive peptides are uncommon, making dermorphin important in research on peptide stereochemistry as well as opioid-receptor pharmacology.
Early pharmacology papers documented strong activity at opioid receptors in experimental systems and described high potency in animal assays.
That pharmacological potency is exactly why discussion must remain firmly in the laboratory-research context. An opioid peptide should not be framed as a casual wellness, performance, or self-experimentation product.
CertaPeptides currently lists Dermorphin as a laboratory research compound, identifies it as a peptide associated with mu-opioid receptor research, and states that it is not intended for human or animal use.
For qualified research laboratories, the useful scientific questions include receptor binding, ligand structure, stereochemistry, D-amino-acid effects on peptide degradation, and structure-activity relationships.
Those are research questions. They are not administration instructions.
A concise comparison of the eight names
| Compound | Basic identity | Main research context | Important documentation issue |
|---|---|---|---|
| SEMAX | Synthetic ACTH(4-7)-derived heptapeptide with PGP extension | Neurotrophin, neural signaling and experimental neuroscience literature | Confirm exact sequence, lot identity, purity/identity evidence |
| SELANK | Tuftsin-derived synthetic heptapeptide | GABA-related, neurochemical and immunomodulatory research | Distinguish Selank-specific evidence from tuftsin background |
| ADAMAX | Commercially described vasopressin-family/bioregulator peptide | Memory and neuropeptide research context | Direct independent literature under exact compound name is limited |
| PE-22-28 | Seven-residue spadin-derived peptide | TREK-1 channel, cellular and animal research | Match sequence/identity to published spadin-analogue literature |
| Cerebrolysin | Porcine-brain-derived peptide/amino-acid mixture | Neurological research literature | Mixture requires composition-aware documentation, not sequence-only thinking |
| VIP | Endogenous vasoactive intestinal peptide | Neuroendocrine, immune, GI, vascular and circadian signaling | Broad biology requires hypothesis-specific interpretation |
| DSIP | Delta sleep-inducing peptide/nonapeptide research entity | Historical sleep and neuroendocrine research | Biological role remains uncertain; do not let the name overstate evidence |
| Dermorphin | Natural D-amino-acid-containing opioid heptapeptide | Opioid-receptor and peptide-stereochemistry research | Potent pharmacology makes strict research-use framing essential |
The table is deliberately descriptive rather than therapeutic. It tells a researcher what kind of molecule or preparation is being discussed and where the documentation problem changes.
What a COA can establish — and what it cannot
The words "Certificate of Analysis" are often treated as a universal quality seal. They are not.
A COA is useful only to the extent that its tests, sample identification, methods, results, and traceability answer the scientific question being asked.
For peptide procurement, several analytical concepts are commonly confused.
Identity
Identity asks whether the material is the intended compound.
Mass spectrometry may contribute to identity verification by showing a molecular mass or mass-related pattern consistent with the expected molecule. Other techniques can also be relevant depending on the material.
Identity is not the same as purity.
A sample can contain a highly pure substance that is nevertheless the wrong substance.
Chromatographic purity
HPLC or related chromatographic methods can estimate how much of the detected material corresponds to a principal chromatographic peak under specified conditions.
A reported "99%" result should therefore be interpreted in relation to the method.
It does not automatically mean that 99% of the vial's physical mass is the desired peptide.
It does not automatically quantify every salt, counterion, water molecule, excipient, residual solvent, or undetected impurity.
And it does not independently establish identity unless identity information is also available.
Content or quantity
Content answers a different question: how much of the intended material is present.
A sample could potentially have high chromatographic purity but a different total content than expected. That is why purity and content should not be treated as synonyms.
Lot matching
A technically impressive report becomes much less useful if the researcher cannot determine whether it belongs to the supplied vial.
The lot or batch identifier on the physical product should correspond to the documentation associated with that lot.
CertaPeptides' current COA page explicitly distinguishes supplier specifications from independent reports and notes that an independent-report card does not mean every dose or shipped lot was independently tested.
That is a meaningful distinction and one researchers should preserve when describing the product.
A previously published guide to CertaPeptides COA and analytical fields goes deeper into the difference between analytical fields for readers who need that documentation background.
Supplier specification versus independent lot report
These terms are easy to blur in marketing copy.
A supplier batch specification is a stated standard or requirement associated with a product or product class.
An independent laboratory report records measurements made on a submitted sample.
They are not the same object.
If a page says "≥98% supplier batch specification; selected lots independently tested," the accurate interpretation is not "every vial has been independently measured at ≥98%."
The correct interpretation is that the supplier states a batch specification and that particular lots may have additional independent analytical reports.
This is especially important in a catalog containing multiple sizes. A report associated with a 10mg lot, for example, should not automatically be described as direct testing of a different size unless the documentation actually establishes that relationship.
Researchers should preserve those distinctions when recording procurement evidence.
Why one purity number cannot compare all eight compounds
Imagine comparing a Semax HPLC percentage with documentation for Cerebrolysin.
Semax is a sequence-defined peptide.
Cerebrolysin is a heterogeneous peptide preparation.
The same number would not carry the same meaning.
Now compare either of those with VIP, an endogenous peptide that may be used in a receptor assay. A laboratory may need sequence identity, concentration accuracy, biological activity, or other assay-specific information.
Then consider Dermorphin. Stereochemistry is highly relevant because D-alanine is central to its identity and pharmacology.
The phrase "99% purity" alone cannot answer every one of those questions.
A meaningful procurement record should therefore connect the analytical method to the molecular question.
That is a better standard than choosing whichever product page displays the largest percentage.
Evidence hierarchy: do not mix cell, animal, and human findings
One recurring problem in peptide content is the compression of very different evidence types into a single sentence.
For example:
A cellular experiment may show receptor binding, gene expression, or ion-channel effects.
An animal experiment may show a behavioral, molecular, physiological, or histological change.
A human observational study may identify an association.
A controlled human trial may test a predefined clinical endpoint.
These are not equivalent layers of evidence.
PE-22-28 provides a clear example. The 2017 work on shortened spadin analogues included in-vitro electrophysiology and animal experiments. Both are scientifically useful, but neither should be rewritten as proof of a clinical antidepressant effect.
Semax likewise has experimental animal literature related to neurotrophin expression. That finding should remain attached to the model in which it was measured.
Selank has molecular and functional-connectivity literature, but that does not transform a laboratory research listing into a medical treatment recommendation.
DSIP demonstrates an additional point: even decades of papers do not guarantee that a biological hypothesis becomes settled.
Cerebrolysin has a comparatively extensive human clinical literature, yet systematic reviews and later assessments still discuss uncertainty and inconsistent findings.
Evidence should therefore be classified, not simply counted.
The importance of exact names in literature searches
Minor punctuation differences can matter.
"PE-22-28," "PE 22-28," and "PE22-28" may retrieve different databases or commercial pages.
"VIP" is extremely ambiguous outside a biological context and can mean "very important person" in ordinary search results.
"Semax + Selank Blend" is not the same analytical object as a Semax-only or Selank-only vial.
"Cerebrolysin 60mg" is a commercial presentation of a complex preparation, not the name of a single 60mg peptide sequence.
"ADAMAX" may be especially sensitive to naming ambiguity because the exact independent literature is limited.
A laboratory literature record should therefore include the exact product name, expected molecular identity, common aliases where justified, and identifiers such as CAS numbers only after they have been independently checked.
Do not allow a convenient name to substitute for chemical identity.
LOOT30 reminder for qualified research procurement
For qualified research buyers who have already determined that a listed compound is appropriate for a legitimate laboratory protocol, CertaPeptides' campaign code is LOOT30 for up to 30% off.
The discount does not change any of the scientific checks described above. Product identity, lot documentation, experimental suitability, institutional approval, shipping eligibility, and applicable local rules should still be evaluated independently.
Current CertaPeptides documentation and shipping context
As of September 11, 2026, CertaPeptides' official shipping page states that the company ships across all 27 EU member states plus Switzerland, the United Kingdom, Iceland, and Serbia.
The same policy page currently describes different carrier arrangements by destination and provides separate delivery estimates and rates. Those operational details can change and should therefore be checked at the time of procurement rather than copied permanently into a laboratory SOP.
For returns, the current official policy describes a 14-day window for eligible unopened products and asks customers to obtain an RMA before returning material. It also contains specific provisions for damaged shipments and purity-related claims.
Shipping availability should not be confused with regulatory permission. A carrier accepting a parcel to a country does not by itself establish lawful importation, possession, experimental use, customs treatment, or institutional authorization.
The recipient remains responsible for applicable requirements.
Documentation questions researchers should be able to answer
A procurement record for any of these compounds is stronger when a later reviewer can reconstruct what was purchased and why.
The essential questions are simple:
- What exact molecule or preparation was ordered?
- What lot or batch was received?
- What supplier specification applied?
- Was there an independent report for the exact lot?
- Which analytical methods were used?
- Did the report assess identity, purity, content, or another characteristic?
- Does the literature being cited actually study the same compound?
- Is the cited evidence in vitro, animal, observational, or human?
- Are conclusions being limited to the evidence type?
- Is the material restricted to laboratory research under the supplier's terms?
Answering those questions does more for reproducibility than collecting promotional adjectives.
Frequently asked questions
Is Semax the same as Selank?
No. Both are synthetic heptapeptides and both contain a Pro-Gly-Pro motif, but Semax is derived from an ACTH-fragment research lineage whereas Selank is based on tuftsin. They have different sequences, research histories, and proposed mechanisms.
Is PE-22-28 another version of Semax?
No. PE-22-28 comes from research on shortened spadin analogues and TREK-1 channels. It belongs to a different research lineage.
Is Cerebrolysin one peptide?
No. Published scientific literature describes Cerebrolysin as a complex preparation containing low-molecular-weight peptides and amino acids derived from porcine brain. That makes its analytical interpretation different from a single sequence-defined peptide.
What does VIP mean?
VIP means vasoactive intestinal peptide. It is an endogenous signaling peptide involved in multiple neuroendocrine and peripheral systems, not only gastrointestinal signaling.
Does the name DSIP prove that it causes sleep?
No. DSIP stands for delta sleep-inducing peptide because of its historical research context, but later reviews have emphasized uncertainty surrounding its endogenous biological role and the strength of the sleep-factor hypothesis.
Why is Dermorphin unusual?
One major reason is its D-alanine residue. D-amino acids are uncommon in naturally occurring bioactive peptides, and this structural feature is important in dermorphin's stability and opioid-receptor pharmacology.
Does a high HPLC percentage prove that a peptide is correctly identified?
Not by itself. Chromatographic purity and molecular identity are different analytical questions. Researchers should examine which tests were actually performed.
Does an independent report on one lot apply to every lot?
Not necessarily. The batch or lot on the report should be compared with the material actually received. CertaPeptides' current COA language itself distinguishes selected independent reports from broader supplier batch specifications.
Can published animal findings be described as proven human benefits?
No. Preclinical evidence should remain identified as preclinical evidence. Animal or cellular findings should not be converted into human medical claims.
Are these products intended for self-experimentation?
No. The CertaPeptides product pages and research-use statements describe these materials as laboratory research products and not for human or veterinary use.
Final perspective
SEMAX, SELANK, ADAMAX, PE-22-28, Cerebrolysin, VIP, DSIP, and Dermorphin become much easier to understand when the researcher stops treating them as a single "neuropeptide" bucket.
Semax is an ACTH-fragment-derived synthetic peptide.
Selank is tuftsin-derived.
PE-22-28 emerges from spadin and TREK-1 research.
VIP is a broad endogenous signaling peptide.
DSIP carries a historically important but scientifically unresolved sleep-related identity.
Dermorphin is a structurally unusual natural opioid peptide containing D-alanine.
Cerebrolysin is a heterogeneous peptide preparation rather than a single short peptide.
Adamax requires particular caution because commercial descriptions are easier to locate than a deep independent literature under the exact compound name.
These differences determine what should be searched in the scientific literature, what analytical documentation is appropriate, what claims can responsibly be made, and how procurement records should be interpreted.
The most useful research question is therefore not simply, "What purity percentage does the page show?"
It is:
What exactly is this material, what evidence supports its identity, what experiment is it appropriate for, and does the documentation actually correspond to the lot in front of the researcher?
For qualified laboratory researchers who have completed those checks, visit CertaPeptides through the LOOT30 research-catalog link and use LOOT30 for up to 30% off.
Research-use reminder: CertaPeptides products referenced in this article are for controlled laboratory and in-vitro research only. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, prevention, clinical application, supplements, cosmetics, or personal experimentation.
Top comments (0)